Abstract
An important area of controversy in Helicobacter pylori eradication is the apparent difference in eradication rates seen in different countries and populations. A recent meta-analysis showed that several factors may affect the outcome of therapy. Individuals residing in northeast Asia had higher eradication rates than those residing in Europe or other areas of Asia. Triple and quadruple drug therapies had significantly higher eradication rates than did dual drug therapies. Treatment regimens that lasted longer than 14 days were better than those that lasted less than seven days, but there was no significant advantage for 10 day therapy over seven day therapy. A number of factors may play a role in determining the regional and geographical differences in H pylori eradication therapy. Included in these factors are genetic differences in the metabolism of the proton pump inhibitor, which can alter the availability of antimicrobials in the stomach. Regional differences in antimicrobial resistance also affect the outcome of therapy. Some studies suggest that the degree of gastritis and the nature of the underlying disease may affect the outcome of therapy, but the data are controversial. Understanding the regional and geographical differences in H pylori eradication can help physicians select the optimal treatment regimen in different regions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Canadian Journal of Gastroenterology and Hepatology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.